Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol

William O. Kline, Frank J. Panaro, Hayung Yang, Sue C. Bodine

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Clenbuterol and other β2-adrenergic agonists are effective at inducing muscle growth and attenuating muscle atrophy through unknown mechanisms. This study tested the hypothesis that clenbuterol-induced growth and muscle sparing is mediated through the activation of Akt and mammalian target of rapamycin (mTOR) signaling pathways. Clenbuterol was administered to normal weight-bearing adult rats to examine the growth-inducing effects and to adult rats undergoing muscle atrophy as the result of hindlimb suspension or denervation to examine the muscle-sparing effects. The pharmacological inhibitor rapamycin was administered in combination with clenbuterol in vivo to determine whether activation of mTOR was involved in mediating the effects of clenbuterol. Clenbuterol administration increased the phosphorylation status of PKB/Akt, S6 kinase 1/p70s6k, and eukaryotic initiation factor 4E binding protein 1/PHAS-1. Clenbuterol treatment induced growth by 27-41% in normal rats and attenuated muscle loss during hindlimb suspension by 10-20%. Rapamycin treatment resulted in a 37-97% suppression of clenbuterol-induced growth and a 100% reduction of the muscle-sparing effect. In contrast, rapamycin was unable to block the muscle-sparing effects of clenbuterol after denervation. Clenbuterol was also shown to suppress the expression of the MuRF1 and MAFbx transcripts in muscles from normal, denervated, and hindlimb-suspended rats. These results demonstrate that the effects of clenbuterol are mediated, in part, through the activation of Akt and mTOR signaling pathways.

Original languageEnglish (US)
Pages (from-to)740-747
Number of pages8
JournalJournal of Applied Physiology
Volume102
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

Clenbuterol
Sirolimus
Muscles
Growth
Hindlimb Suspension
Muscular Atrophy
Denervation
Eukaryotic Initiation Factor-4E
Ribosomal Protein S6 Kinases
70-kDa Ribosomal Protein S6 Kinases
Adrenergic Agonists
Weight-Bearing
Hindlimb
Carrier Proteins

Keywords

  • β-adrenergic agonists
  • Akt/PKB
  • MaFBx
  • mTOR
  • MuRF1

ASJC Scopus subject areas

  • Physiology
  • Endocrinology
  • Orthopedics and Sports Medicine
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. / Kline, William O.; Panaro, Frank J.; Yang, Hayung; Bodine, Sue C.

In: Journal of Applied Physiology, Vol. 102, No. 2, 02.2007, p. 740-747.

Research output: Contribution to journalArticle

Kline, William O. ; Panaro, Frank J. ; Yang, Hayung ; Bodine, Sue C. / Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. In: Journal of Applied Physiology. 2007 ; Vol. 102, No. 2. pp. 740-747.
@article{35a623ef498f44ea997522c263e265a9,
title = "Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol",
abstract = "Clenbuterol and other β2-adrenergic agonists are effective at inducing muscle growth and attenuating muscle atrophy through unknown mechanisms. This study tested the hypothesis that clenbuterol-induced growth and muscle sparing is mediated through the activation of Akt and mammalian target of rapamycin (mTOR) signaling pathways. Clenbuterol was administered to normal weight-bearing adult rats to examine the growth-inducing effects and to adult rats undergoing muscle atrophy as the result of hindlimb suspension or denervation to examine the muscle-sparing effects. The pharmacological inhibitor rapamycin was administered in combination with clenbuterol in vivo to determine whether activation of mTOR was involved in mediating the effects of clenbuterol. Clenbuterol administration increased the phosphorylation status of PKB/Akt, S6 kinase 1/p70s6k, and eukaryotic initiation factor 4E binding protein 1/PHAS-1. Clenbuterol treatment induced growth by 27-41{\%} in normal rats and attenuated muscle loss during hindlimb suspension by 10-20{\%}. Rapamycin treatment resulted in a 37-97{\%} suppression of clenbuterol-induced growth and a 100{\%} reduction of the muscle-sparing effect. In contrast, rapamycin was unable to block the muscle-sparing effects of clenbuterol after denervation. Clenbuterol was also shown to suppress the expression of the MuRF1 and MAFbx transcripts in muscles from normal, denervated, and hindlimb-suspended rats. These results demonstrate that the effects of clenbuterol are mediated, in part, through the activation of Akt and mTOR signaling pathways.",
keywords = "β-adrenergic agonists, Akt/PKB, MaFBx, mTOR, MuRF1",
author = "Kline, {William O.} and Panaro, {Frank J.} and Hayung Yang and Bodine, {Sue C.}",
year = "2007",
month = "2",
doi = "10.1152/japplphysiol.00873.2006",
language = "English (US)",
volume = "102",
pages = "740--747",
journal = "Journal of Applied Physiology",
issn = "8750-7587",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol

AU - Kline, William O.

AU - Panaro, Frank J.

AU - Yang, Hayung

AU - Bodine, Sue C.

PY - 2007/2

Y1 - 2007/2

N2 - Clenbuterol and other β2-adrenergic agonists are effective at inducing muscle growth and attenuating muscle atrophy through unknown mechanisms. This study tested the hypothesis that clenbuterol-induced growth and muscle sparing is mediated through the activation of Akt and mammalian target of rapamycin (mTOR) signaling pathways. Clenbuterol was administered to normal weight-bearing adult rats to examine the growth-inducing effects and to adult rats undergoing muscle atrophy as the result of hindlimb suspension or denervation to examine the muscle-sparing effects. The pharmacological inhibitor rapamycin was administered in combination with clenbuterol in vivo to determine whether activation of mTOR was involved in mediating the effects of clenbuterol. Clenbuterol administration increased the phosphorylation status of PKB/Akt, S6 kinase 1/p70s6k, and eukaryotic initiation factor 4E binding protein 1/PHAS-1. Clenbuterol treatment induced growth by 27-41% in normal rats and attenuated muscle loss during hindlimb suspension by 10-20%. Rapamycin treatment resulted in a 37-97% suppression of clenbuterol-induced growth and a 100% reduction of the muscle-sparing effect. In contrast, rapamycin was unable to block the muscle-sparing effects of clenbuterol after denervation. Clenbuterol was also shown to suppress the expression of the MuRF1 and MAFbx transcripts in muscles from normal, denervated, and hindlimb-suspended rats. These results demonstrate that the effects of clenbuterol are mediated, in part, through the activation of Akt and mTOR signaling pathways.

AB - Clenbuterol and other β2-adrenergic agonists are effective at inducing muscle growth and attenuating muscle atrophy through unknown mechanisms. This study tested the hypothesis that clenbuterol-induced growth and muscle sparing is mediated through the activation of Akt and mammalian target of rapamycin (mTOR) signaling pathways. Clenbuterol was administered to normal weight-bearing adult rats to examine the growth-inducing effects and to adult rats undergoing muscle atrophy as the result of hindlimb suspension or denervation to examine the muscle-sparing effects. The pharmacological inhibitor rapamycin was administered in combination with clenbuterol in vivo to determine whether activation of mTOR was involved in mediating the effects of clenbuterol. Clenbuterol administration increased the phosphorylation status of PKB/Akt, S6 kinase 1/p70s6k, and eukaryotic initiation factor 4E binding protein 1/PHAS-1. Clenbuterol treatment induced growth by 27-41% in normal rats and attenuated muscle loss during hindlimb suspension by 10-20%. Rapamycin treatment resulted in a 37-97% suppression of clenbuterol-induced growth and a 100% reduction of the muscle-sparing effect. In contrast, rapamycin was unable to block the muscle-sparing effects of clenbuterol after denervation. Clenbuterol was also shown to suppress the expression of the MuRF1 and MAFbx transcripts in muscles from normal, denervated, and hindlimb-suspended rats. These results demonstrate that the effects of clenbuterol are mediated, in part, through the activation of Akt and mTOR signaling pathways.

KW - β-adrenergic agonists

KW - Akt/PKB

KW - MaFBx

KW - mTOR

KW - MuRF1

UR - http://www.scopus.com/inward/record.url?scp=33846885682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846885682&partnerID=8YFLogxK

U2 - 10.1152/japplphysiol.00873.2006

DO - 10.1152/japplphysiol.00873.2006

M3 - Article

VL - 102

SP - 740

EP - 747

JO - Journal of Applied Physiology

JF - Journal of Applied Physiology

SN - 8750-7587

IS - 2

ER -